Literature DB >> 18333894

Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting.

Saurabh Lodha1, Sarika Saggar, Julide T Celebi, David N Silvers.   

Abstract

BACKGROUND: The gold standard for diagnosing melanocytic neoplasms is by histopathologic examination. However, lack of agreement among expert dermatopathologists in evaluating these tumors has been well established in experimental settings.
OBJECTIVE: This study examines the discordance among dermatopathologists in evaluating difficult melanocytic neoplasms in a clinical setting where the diagnosis impacts patient management.
METHODS: Retrospective review of consultation reports over a 6-year period.
RESULTS: There was complete agreement among the consultants in 54.5% of the cases. However, a high level of disagreement was found in 25% of the cases. LIMITATIONS: The analysis was limited to two consultant dermatopathologists.
CONCLUSIONS: There are limitations to the practical applications of histologic criteria for diagnosing difficult melanocytic tumors. It is not malpractice for a pathologist to have rendered a diagnosis that did not predict clinical outcome as long as 'standard of care' has been followed in his/her evaluation of the specimen.

Entities:  

Mesh:

Year:  2008        PMID: 18333894     DOI: 10.1111/j.1600-0560.2007.00970.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  24 in total

Review 1.  The digital age of melanoma management: detection and diagnostics.

Authors:  Alexander L Fogel; Kavita Sarin
Journal:  Melanoma Manag       Date:  2015-11-26

Review 2.  Invited Review Article: Pump-probe microscopy.

Authors:  Martin C Fischer; Jesse W Wilson; Francisco E Robles; Warren S Warren
Journal:  Rev Sci Instrum       Date:  2016-03       Impact factor: 1.523

3.  Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.

Authors:  Maija Kiuru; Danielle M Tartar; Lihong Qi; Danyang Chen; Lan Yu; Thomas Konia; John D McPherson; William J Murphy; Maxwell A Fung
Journal:  J Am Acad Dermatol       Date:  2018-04-11       Impact factor: 11.527

4.  Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma.

Authors:  Jeffrey P North; John T Vetto; Rajmohan Murali; Kevin P White; Clifton R White; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2011-08       Impact factor: 6.394

5.  Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions.

Authors:  Eugen C Minca; Rami N Al-Rohil; Min Wang; Paul W Harms; Jennifer S Ko; Angela M Collie; Ivanka Kovalyshyn; Victor G Prieto; Michael T Tetzlaff; Steven D Billings; Aleodor A Andea
Journal:  Mod Pathol       Date:  2016-05-13       Impact factor: 7.842

6.  Embryonic signaling in melanoma: potential for diagnosis and therapy.

Authors:  Luigi Strizzi; Katharine M Hardy; Gina T Kirsammer; Pedram Gerami; Mary J C Hendrix
Journal:  Lab Invest       Date:  2011-04-04       Impact factor: 5.662

7.  Comparative genomic hybridization for the diagnosis of melanoma.

Authors:  Christopher Vanison; Neil Tanna; Ananth S Murthy
Journal:  Eur J Plast Surg       Date:  2009-12-09

8.  Reliability and validity of mobile teledermatology in human immunodeficiency virus-positive patients in Botswana: a pilot study.

Authors:  Rahat S Azfar; Robert A Lee; Leslie Castelo-Soccio; Martin S Greenberg; Warren B Bilker; Joel M Gelfand; Carrie L Kovarik
Journal:  JAMA Dermatol       Date:  2014-06       Impact factor: 10.282

9.  Diagnostic role of chromosomal instability in melanoma.

Authors:  Nitika Dabas; Diana M Byrnes; Ashley M Rosa; Mark S Eller; James M Grichnik
Journal:  J Skin Cancer       Date:  2012-10-18

10.  FISH as an effective diagnostic tool for the management of challenging melanocytic lesions.

Authors:  Mathew W Moore; Robert Gasparini
Journal:  Diagn Pathol       Date:  2011-08-11       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.